ArticleJournal of the National Cancer Institute2022

Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research.

Natalia Kunst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.